Relationship between Intermittent Claudication, Inflammation, Thrombosis, and Recurrent Cardiac Events among Survivors of Myocardial Infarction

Archives of Internal Medicine

Volumn 164, Issue 4, 2004, Pages 440-446

  Narins, Craig R ^a   Zareba, Wojciech ^a   Moss, Arthur J ^a   Marder, Victor J ^b   Ridker, Paul M ^c   Krone, Ronald J ^d   Lichstein, Edgar ^e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; LIPID; NITRATE; PROCOAGULANT; SERUM AMYLOID A; WARFARIN;

ADULT; AGED; ANAMNESIS; ARTERY DISEASE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD SAMPLING; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMOSTASIS; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; SMOKING; THROMBOSIS; TOBACCO;

COMORBIDITY; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; THROMBOSIS;

EID: 1242320104     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.4.440     Document Type: Article

References (28)

1. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Yaari S, Goldbourt U. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol. 1997;7:180-187.
2. Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001;33:251-258.
3. Vogt MT, Cauley JA, Newman AB, Juller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;270:465-469.
4. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
5. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ, Coronary Artery Surgery Study (CASS) Investigators. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. J Am Coll Cardiol. 1994;23:1091-1095.
6. Magovern JA, Sakert T, Magovern GJ, et al. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol. 1996;28:1147-1153.
7. Krumholz HM, Chen J, Chen YT, Wang Y, Radford MJ. Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol. 2001;38:453-459.
8. Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993;125:863-872.
9. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation. 1999;99:2517-2522.
10. Rifai N, Tracy R, Ridker P. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
11. Dawson I, van Bockel JH, Brand R. Late nonfatal and fatal cardiac events after infrainguinal bypass for femoropopliteal occlusive disease during a thirty-one-year period. J Vasc Surg. 1993;18:249-260.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337:356]. N Engl J Med. 1997;336:973-979.
13. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337:356]. N Engl J Med. 1997;336:973-979.
14. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
15. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
16. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103:2323-2327.
17. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of C-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease: baseline findings of the PAIS project. Atherosclerosis. 2001;156:451-456.
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
19. Ridker PM, Stampfer MJ, Rffai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481-2485.
20. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
21. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992-997.
22. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823-827.
23. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol After Acute Myocardial Infarction. N Engl J Med. 1985;313:1055-1058.
24. Gottlieb SS, McCarter RJ, Vogel RA. Effect of β-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
25. Smith RS, Warren DJ. Effect of β-blocking drugs on peripheral blood flow in intermittent claudication. J Cardiovasc Pharmacol. 1982;4:2-4.
26. Hlatt WR, Stoll S, Nies AS. Effect of β-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation. 1985;72:1226-1231.
27. Radack K, Deck C. β-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151:1769-1776.
28. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.